Company Highlights

Patrys PAT-SM6 melanoma trial completed

Patrys recently completed a Phase I PAT-SM6 clinical trial in melanoma at the Royal Adelaide and Princess Alexander Hospitals. Under the trial design, three different dose levels were evaluated in three cohorts of patients.

More...

Patrys PAT-SM6 shows promise in multiple myeloma, clinical trial planning underway

In December 2011, Patrys announced it was planning to conduct a multiple myeloma trial in Germany in 2012.

More...

PAT-SM6 inhibits metastases in melanoma cancer model

In August 2011, Patrys announced positive results from a new proof-of-concept study on its lead product PAT-SM6 in an animal model. The study examined PAT-SM6’s activity against metastatic melanoma.

More...

PAT-SC1 shows significant survival benefit in gastric cancer trial

In September 2011, Patrys announced positive results from a follow-up of gastric cancer patients who were treated with anti-cancer compound PAT-SC1.

More...

Welcome to Patrys

Patrys is a publicly-listed company on the Australian Securities Exchange (ASX:PAB). Our principal focus is on the development of a completely new type of product for the treatment of cancer – natural human antibodies. These natural human antibodies offer the promise of increased potency coupled with greater safety as compared to existing cancer treatments.